New York Proton Center and WiTT Group form strategic partnership to help patients address non-clinical cancer care costs

FDA guidance provides new details on diversity action plans for clinical studies

FDA issued a draft guidance, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” to assist medical product sponsors in submitting diversity action plans to support certain clinical studies.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Among cancer survivors, LGBTQ+ individuals report higher prevalence of chronic health conditions, disabilities, other limitations

Cancer survivors who identify as lesbian, gay, bisexual, transgender, queer, or anything other than straight and cisgender experience more chronic health conditions, disabilities, and other physical and cognitive limitations than non-LGBTQ+ cancer survivors; however, the prevalence of most conditions was highest among transgender or gender non-conforming individuals, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.

June 21, 2024

Vol.50 No.25

Clinical Roundup

Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations

Friends of Cancer Research characterized postmarketing requirements and commitments over the last decade. The perspective article, titled “An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials,” provides insights into FDA’s expectations for representation of race and ethnicity in oncology clinical trials.

June 21, 2024

Vol.50 No.25

Clinical Roundup

Atlantic Health System, Mevion collaborate to bring proton therapy technology to Carol G. Simon Cancer Center

Atlantic Health System, an integrated health care system setting standards for quality health care, and Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, have announced Atlantic Health System’s plans to acquire and install a MEVION S250-FIT Proton Therapy System at the Carol G. Simon Cancer Center.

June 14, 2024

Vol.50 No.24

Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows

Directors of NCI-designated cancer centers are facing a new set of challenges in a polarizing, high-stakes election year.

June 07, 2024

Vol.50 No.23

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Fred Hutch’s Christopher Li: Cancer centers should commit more resources to meet NCI’s Plan to Enhance Diversity requirements

Christopher Li, the Helen G. Edson Endowed Chair for Breast Cancer Research at Fred Hutchinson Cancer Center, understands what it means to be an underrepresented minority at each stage of his academic career.

June 07, 2024

Vol.50 No.23

By Matthew Bin Han Ong

New York Proton Center and WiTT Group form strategic partnership to help patients address non-clinical cancer care costs

YOU MAY BE INTERESTED IN

FDA guidance provides new details on diversity action plans for clinical studies

Among cancer survivors, LGBTQ+ individuals report higher prevalence of chronic health conditions, disabilities, other limitations

Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations

Atlantic Health System, Mevion collaborate to bring proton therapy technology to Carol G. Simon Cancer Center

Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows

Fred Hutch’s Christopher Li: Cancer centers should commit more resources to meet NCI’s Plan to Enhance Diversity requirements

Renew today!

Subscriber content

Login